SCHEMBL22069530

SCHEMBL22069530

CCCCCc1cc(O)c2c(c1)OC(C)(C)C=C2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 11/20 0.67
▸ CNR1 P21554 10/20 0.67
▸ TRPV1 Q8NER1 5/20 0.67
▸ TRPA1 O75762 2/20 0.67
▸ SLC6A2 P23975 2/20 0.67
▸ SLC6A4 P31645 2/20 0.67
▸ TRPV3 Q8NET8 2/20 0.67
▸ TRPV4 Q9HBA0 2/20 0.67
▸ TRPV2 Q9Y5S1 2/20 0.67
▸ LDHA P00338 2/20 0.67
▸ TRPM8 Q7Z2W7 2/20 0.67
▸ SLC6A3 Q01959 1/20 0.67
▸ CYP1A1 P04798 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2A6 P11509 1/20 0.47
▸ CYP2B6 P20813 1/20 0.47
▸ HTR2A P28223 1/20 0.47
▸ OPRM1 P35372 1/20 0.47
▸ CYP2J2 P51589 1/20 0.47
▸ CYP1B1 Q16678 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21155333 0.81 TRPV1 (0.78) CNR2CNR1TRPV1TRPA1SLC6A2
SCHEMBL25367522 0.81 ALOX5 (0.50) CNR2CNR1TRPV1TRPA1SLC6A2
Cannabichromene SCHEMBL22095415 0.80 CNR1 (1.00) CNR2CNR1TRPV1TRPA1SLC6A2
Cannabichromene SCHEMBL29939768 0.80 CNR1 (1.00) CNR2CNR1TRPV1TRPA1SLC6A2
SCHEMBL24757567 0.80 CNR2 (0.66) CNR2CNR1TRPV1TRPA1SLC6A2
Cannabichromene SCHEMBL144938 0.80 CNR1 (1.00) CNR2CNR1TRPV1TRPA1SLC6A2
Cannabichromene SCHEMBL22095394 0.80 CNR1 (1.00) CNR2CNR1TRPV1TRPA1SLC6A2
SCHEMBL31545046 0.80 CNR2 (0.68) CNR2CNR1TRPV1TRPA1SLC6A2
SCHEMBL20193861 0.80 CNR2 (0.65) CNR2CNR1TRPV1TRPA1SLC6A2
SCHEMBL29647739 0.80 CNR1 (0.98) CNR2CNR1TRPV1TRPA1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260007688-A1 SYNTHETIC ANALOGS OF CANNABINOL (CBN) FOR THE TREATMENT OF AGERELATED NEUROLOGICAL DISORDERS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2026-01-08 — — US claimed
WO-2024148193-A1 SYNTHETIC ANALOGS OF CANNABINOL (CBN) FOR THE TREATMENT OF AGE-RELATED NEUROLOGICAL DISORDERS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2024-07-11 — — WO claimed
US-20260007688-A1 SYNTHETIC ANALOGS OF CANNABINOL (CBN) FOR THE TREATMENT OF AGERELATED NEUROLOGICAL DISORDERS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2026-01-08 — — US disclosed
WO-2024148193-A1 SYNTHETIC ANALOGS OF CANNABINOL (CBN) FOR THE TREATMENT OF AGE-RELATED NEUROLOGICAL DISORDERS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2024-07-11 — — WO disclosed
WO-2020120582-A1 CHROMENIC PHYTOCANNABINOIDS, THEIR SYNTHESIS AND USE IN TREATMENT OR PREVENTION OF DISEASE EMERALD HEALTH BIOTECHNOLOGY ESPAÑA,S.L.U. (ES) 2020-06-18 — — WO disclosed
WO-2020120582-A1 CHROMENIC PHYTOCANNABINOIDS, THEIR SYNTHESIS AND USE IN TREATMENT OR PREVENTION OF DISEASE EMERALD HEALTH BIOTECHNOLOGY ESPAÑA,S.L.U. (ES) 2020-06-18 — — WO disclosed
EP-3666765-A1 CHROMENIC PHYTOCANNABINOIDS, THEIR SYNTHESIS AND USE IN TREATMENT OR PREVENTION OF DISEASE Emerald Health Biotechnology España,S.L.U. (ES) 2020-06-17 — — EP disclosed
EP-3666765-A1 CHROMENIC PHYTOCANNABINOIDS, THEIR SYNTHESIS AND USE IN TREATMENT OR PREVENTION OF DISEASE Emerald Health Biotechnology España,S.L.U. (ES) 2020-06-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260007688-A1 SYNTHETIC ANALOGS OF CANNABINOL (CBN) FOR THE TREATMENT OF AGERELATED NEUROLOGICAL DISORDERS AIFM2, FECH, NLN CNR2 4/4885CNR1 5/4885TRPV1 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback